Guckenbiehl W, Just H, Olbermann M, Lang K F
Med Klin. 1976 Apr 2;71(14):586-92.
A new sustained-action preparation of quinidine-bisulfate (BM-Chinidin Retard) was investigated in 21 patients. After a single oral dose of 1 g peak plasma levels are reached within 3-4 hours with an unsubstantial decrease during the following 4 hours. After 2 g in three divided doses within 12 hours maximal plasma levels are found after 14-16 hours, but an effective level is reached as early as 4 hours after the first dose. With 1 g Chinidin retard given in two doses within 24 hours, varying plasma concentrations are reached after 24 hours, reaching a maximum after 48 hours and decreasing to a medium level thereafter. The minimal concentrations measured were 23 percent lower than the maximal concentrations suggesting that during longterm application rather stable plasma levels are achieved. The effectiveness of the preparation was demonstrated in patients with atrial fibrillation and flutter, supra-ventricular and ventricular premature beats. Longterm treatment was attempted in all patients. Quinidine effectiveness and plasma concentrations were constant throughout the observation period. Side effects were rare: inappetence, vertigo, and headache were observed transiently in 4 patients without necessitating a change in medication. ECG-alterations occurred as described for quinidine-prepartions in general.
对21例患者研究了一种新的硫酸奎尼丁长效制剂(BM - Chinidin Retard)。单次口服1g后,3 - 4小时内达到血浆峰值水平,随后4小时内下降不明显。12小时内分三次服用2g后,14 - 16小时达到最大血浆水平,但首次给药后4小时就可达到有效水平。24小时内分两次服用1g Chinidin retard,24小时后血浆浓度各异,48小时后达到最大值,此后降至中等水平。测得的最低浓度比最高浓度低23%,这表明长期应用时可达到相当稳定的血浆水平。该制剂对心房颤动和扑动、室上性和室性早搏患者有效。所有患者均尝试进行长期治疗。在整个观察期内,奎尼丁的疗效和血浆浓度保持恒定。副作用很少见:4例患者短暂出现食欲不振、眩晕和头痛,无需改变用药。心电图改变与一般奎尼丁制剂描述的情况相同。